Literature DB >> 1761814

Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism.

S Mariotti1, P Caturegli, G Barbesino, G F Del Prete, L Chiovato, A Pinchera.   

Abstract

High serum concentration of soluble interleukin-2 receptor (sIL-2R) is considered a reliable marker of T lymphocyte activation. It has been recently reported that sIL-2R levels are increased in untreated Graves' disease. This finding has been interpreted as the consequence of an active autoimmune state, but the relevance of the thyroid function per se was not investigated. In the present study we assayed sIL-2R by ELISA in 20 normal subjects and in a series of patients with immunogenic (Graves' disease, GD) or nonimmunogenic (toxic adenoma, TA) hyperthyroidism. Significant increased concentrations of sIL-2R were found in 46 patients with untreated hyperthyroid GD (mean +/- SD: 1,683 +/- 1016 U/ml, vs 461 +/- 186 U/ml in normal controls, p less than 0.0001) and in 21 with untreated TA (1,111 +/- 617 U/ml, p less than 0.0001 vs normals). Restoration of the euthyroid state by antithyroid drugs or 131I administration was associated with a normalization of sIL-2R (516 +/- 174 U/ml in 38 patients with GD and 365 +/- 90 U/ml in 12 with TA; p = NS vs normals and p less than 0.001 vs the untreated state for both groups). A highly significant positive correlation between serum sIL-2R and free triiodothyronine (FT3) (r = 0.724, p less than 0.0001) or free thyroxine (FT4) (r = 0.698, p less than 0.0001) concentrations was found in combined sera obtained from all untreated and treated patients, irrespectively of the autoimmune or nonautoimmune nature of the underlying hyperthyroid disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761814     DOI: 10.1007/BF03347915

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  13 in total

1.  Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy.

Authors:  C C Chow; K N Lai; J C Leung; J C Chan; C S Cockram
Journal:  Clin Endocrinol (Oxf)       Date:  1990-09       Impact factor: 3.478

2.  Flow cytometry resonance energy transfer suggests an association between low-affinity interleukin 2 binding sites and HLA class I molecules.

Authors:  A Harel-Bellan; P Krief; L Rimsky; W L Farrar; Z Mishal
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

Review 3.  The interleukin 2 receptor.

Authors:  K A Smith
Journal:  Annu Rev Cell Biol       Date:  1989

4.  Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones.

Authors:  M B Sztein; S A Serrate; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 5.  The soluble interleukin-2 receptor: biology, function, and clinical application.

Authors:  L A Rubin; D L Nelson
Journal:  Ann Intern Med       Date:  1990-10-15       Impact factor: 25.391

6.  Thyroid-thymus interactions during development and aging.

Authors:  N Fabris; E Mocchegiani; S Mariotti; F Pacini; A Pinchera
Journal:  Horm Res       Date:  1989

7.  Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes.

Authors:  K D Leichtling; S A Serrate; M B Sztein
Journal:  Int J Immunopharmacol       Date:  1990

8.  Serum beta 2-microglobulin levels in thyroid diseases.

Authors:  H H Lervang; J Møller-Petersen; J Ditzel
Journal:  J Intern Med       Date:  1989-10       Impact factor: 8.989

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves' disease.

Authors:  C Marcocci; L Chiovato; S Mariotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

View more
  8 in total

1.  Serum-soluble interleukin-2 receptor levels before and after surgical treatment for Graves' disease.

Authors:  S Murakami; A Kobayashi; K Kuma; H Murai; Y Okamura; A Satomi; K Ishida
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

2.  Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis.

Authors:  R C Smallridge; G C Tsokos; K D Burman; L Porter; T Cranston; P P Sfikakis; B L Solomon
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

3.  The Impact of Iodine Exposure in Excess on Hormonal Aspects and Hemato-Biochemical Profile in Rats.

Authors:  Hager Tarek H Ismail
Journal:  Biol Trace Elem Res       Date:  2021-03-30       Impact factor: 3.738

4.  Serum soluble interleukin-2 receptors as an index of the biological activity of thyroid hormones in hyperthyroidism.

Authors:  E Koukkou; P Panayiotidis; N Thalassinos
Journal:  J Endocrinol Invest       Date:  1995-04       Impact factor: 4.256

5.  Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.

Authors:  S Mariotti; G Barbesino; P Caturegli; M Marinò; L Manetti; L Fugazzola; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

6.  Clinical Application Value of High-Frequency Ultrasound Combined with Detection of Serum High Mobility Group Box 1, Soluble IL-2 Receptor, and Thyroglobulin Antibody in Diagnosing Thyroid Cancer.

Authors:  Ning Li; Jiahui Zhang; Xiaojiao Meng; Wenliang Yao
Journal:  J Healthc Eng       Date:  2022-03-29       Impact factor: 2.682

7.  The Predicting Role of Serum TSGF and sIL-2R for the Lymph Node Metastasis of Papillary Thyroid Carcinoma.

Authors:  Xiaoqin Xu; Weigang Wang; Ting Sun; Baoguo Tian; Lili Du; Jiexian Jing
Journal:  Dis Markers       Date:  2022-09-02       Impact factor: 3.464

8.  Biological significance of soluble IL-2 receptor.

Authors:  C Caruso; G Candore; D Cigna; A T Colucci; M A Modica
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.